key: cord-1003670-8l3yviac
authors: Meshram, Hari Shankar; Kute, Vivek B; Patel, Himanshu V; Hegde, Umapati; Das, Pratik; Sil, Keshab; Sahay, Manisha; Raju, Sree Bhushan; Chaudhary, Arpita Roy; Siddini, Vishwanath; Pathak, Vivek; Bahadur, M M; Anand, Urmila; Krishna, Amresh; Abraham, Abi; Patel, Ansy H; Mishra, Vineet; Chauhan, Sanshriti
title: Is early COVID-19 in kidney transplant recipients concerning enough to halt transplantation? A multicenter comparative analysis from India
date: 2021-08-30
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2021.08.034
sha: 56123e3797bdd0197d4f3e4b0d79c1ba61070f6c
doc_id: 1003670
cord_uid: 8l3yviac

Introduction: Limited data exists on the incidence and outcome of early coronavirus disease (COVID-19) in kidney transplantation recipients (KTR). Methods: A retrospective multicentre research was conducted across 12 centers of India. We explored the symptomatology, demographic, laboratory findings and outcome of COVID-19 within 30 days of transplantation. The outcome was compared with the overall KTR and waitlisted patients acquiring COVID-19. Results: The incidence of early COVID-19 was 2.6% (n =22) for the cumulative 838 renal transplants performed since nationwide lockdown in March 2020 till May 2021. Overall, 1049 KTR were diagnosed with COVID-19 and 2% of those had early COVID-19. The median age of the early COVID-19 cohort was 43(31-46) years. COVID-19 severity ranged from asymptomatic (18.2%), mild (59.1%), moderate (9.1%) and severe (13.6%). Among clinical symptoms, Dyspnea and Anosmia were frequent and in laboratory parameters neutrophil lymphocyte ratio, high sensitive C reactive protein and D- dimer were higher in patients requiring oxygen. The mortality in early COVID-19 was not higher than overall KTR (4.5% vs 8.5%; p-value: 1). COVID-19 severity (23.9% vs 15.7%; p-value: 0.0001) and mortality (15.5% vs 8.5%; p-value: 0.001) among waitlisted patients (n = 1703) were higher compared to overall KTR. Conclusion: We report higher burden of COVID-19 in waitlisted patients compared to KTR and a favorable outcome in early COVID-19 in KTR. Our report will help the transplant physicians in dealing with the ongoing dilemma of halting or resuming transplantation in the COVID-19 era.

COVID-19 ceased the transplantation activity in almost all parts of the world for a while and resumption of transplantation became an altogether strenuous task especially in densely populated nations like India with high COVID-19 tally and unprecedented surges. 1 Many transplant centers resumed staged wise transplant activities following national and international advisory guidelines for transplantation during the COVID-19 era. 2 As the safety of donors, recipients and health care workers are jeopardized; the logistics and ethics involved for transplantation in COVID-19 era are intricate. Severe acute respiratory syndrome coronavirus (SARS-CoV2) infection in solid organ transplantation has been extensively reviewed in both developing and emerging nations with wide diversity in clinical profile and outcomes. 3, 4, 5, 6, 7, 8, 9, 10, 11 However, there is scarcity of data from the developing nations about COVID-19 as an early infection, when transplantation was restarted following a halt by the pandemic. Early COVID-19 in a transplant can possibly have lethal outcome. The three major research questions to contemplate in the context of resuming transplantation are: 1) Do KTR acquiring early COVID- 19 have a worse outcome compared to those who acquire COVID-19 later? 2) Does outcome of early COVID-19 poor enough to the extent that it would hinder the transplant activity? 3) Do severity of COVID-19 is worse for the transplant patients compared to the waitlisted patients?

The aim of this report was to study the clinical profile and outcome of early COVID-19 in KTR and compare the outcomes of COVID-19 in KTR with waitlisted patients.

Ethical statement: The study was designed as a retrospective study and was approved by the institutional ethical committee (ECR/143/Inst/GJ/2013/RR- 19) . All transplant activities performed in the centers were in accordance with the regulations of declaration of Helsinki, declaration of Istanbul and THOTA. The research strictly sticks to the STROBE check list for reporting the data.

Data was explored from the following 12 

All KTR with confirmed COVID-19 diagnosed through SARS-CoV2 real time polymerase test (RT-PCR) from nasopharyngeal sample were included from the study period of May 2020 to Jan 2021(n=10). For the two centers (IKDRC and RNT) the data was adjudicated until May 2021. The waitlisted patients detected with COVID-19

were also included in the study. KTR with early COVID-19 were described for symptoms, lab findings and treatment alternatives. The COVID-19 severity was divided as per the WHO grading into asymptomatic, mild, moderate and severe. 12 Transplantation protocol followed in the centers in the COVID-19 era:

All the donor recipient pairs (DRP) were advised to practice COVID-19 etiquettes like social distancing, face masks and hand hygiene for 14 days prior to surgery. All the DRP underwent routine pretransplant evaluation as per the KDIGO guidelines. 13, 14 Additionally, two consecutive negative SARS-CoV2 RT-PCR with normal radiology and no symptoms was mandatory for proceeding for transplant in DRP. Dedicated separate Healthcare worker (HCW) staffs were assigned to minimize the chances of hospital acquired transmission. All the doctors and HCW involved underwent routine preliminary clinical and epidemiological daily checkups for COVID-19. In a nutshell, all the transplantation activity carried out in the COVID-19 era was conducted as per the national guidelines 15 for transplantation. The authors also have previously documented the protocol for donor-recipient management in COVID-19 recovered donors 16 and recipients 17 in the context of living related transplantation.

There was no modification in practice of induction or immunosuppressive drug regimen and the decision was based on patient's immunological profile. The duration of admission before transplant for DRP was restricted to 1 to 2 days. Additionally, the discharge from the hospital after surgery was done as early as possible to prevent hospital acquired infection.

The ideal regimen for the management in early COVID-19 is unknown. As a mark of caution, antimetabolite was stopped in even asymptomatic and mild cases of early COVID-19, while in moderate to severe COVID-19 both CNI and antimetabolite were reduced. Due to the uncertainty in the course of early COVID-19 all patients most patients were hospitalized irrespective of their clinical condition and were strictly followed through telemedicine for any unfavorable outcome once were discharged. Even in the mild cases, some centers have used antiviral like remdesivir. Systemic steroids were used in all of the moderate and severe cases.

A national call was raised to the 21 transplant centers of which data from 12 centers was collected. The detailed pro forma for the study was created by (VBK and HSM) in Microsoft excel sheet and distributed to all the centers through emails. The final data was assembled in a master excel sheet and analyzed in SPSS 21 software. No specified sample size was planned in the study. Continuous data was expressed as median and inter-quartile range (IQR) and categorical data as numbers and percentage. The characteristics of recent transplants were compared between modified WHO ordinal scale ≤ 3 and ≥ 4. The modified WHO ordinal scale 18 used was as follows: 1 =At home with no limitations of activities; 2 = At home with slight limitations; 3 = hospitalized and on ambient air; 4 = low flow oxygen therapy; 5 = high flow oxygen or non re-breather mask; 6 = Bi-level positive pressure ventilation; 7 = mechanical ventilation; 8 = Death. The comparison between the two groups was made through Chi square test with Yates's correction, Fischer test and t test as appropriate. The data comparing the severity of COVID-19 and associated mortality in waitlisted, recent transplants, and overall KTR was also analyzed. The limitation of the design was that the finer details comparing the differences in risk factors for mortality in the three groups was not investigated from all of the centers. A two tailed p-value of less than 0.05 was considered statistically significant.

Since the imposition of a national lockdown in India in late March 2020, a total of 838 renal transplants were performed across 12 centers till May 2021. Deceased donor transplantation contributed only 9.6 % (n=81) of the total transplants. To add, forty seven recovered recipients and twenty recovered donors were transplanted across these centers. Thus, the incidence of early COVID-19 calculated was overall 2.6%. The incidence was higher in deceased transplants (6.1% vs 2.37%; p-value: 0.06) compared to living-related transplants, although not statistically significant. In total, 1049 KTR were diagnosed with COVID-19 and 2% (n =22) of those had early COVID-19. A total of 1703 waitlisted patients were reported in the study.

The median age of the early cohort was 40.5 (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) years with oxygen requirement more in older age group, although statistically insignificant [38(25-45) 13.6%) and interleukin 2 (IL-2) blocker (n =2, 9.1%). There was no difference in severity of COVID-19 as per the native kidney disease as detailed in Table 1 . Presence of more than two co-morbidities was associated with WHO ordinal scale ≥ 4 although statistical difference was not achieved [13(9-22) vs 14 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) ; p value: 0.1]. Hospital acquired COVID-19(n= 4, 18.1%) accounted for a smaller number of cases.

The laboratory parameters which were higher and statistically significant in cases with WHO ordinal scale ≥ 4 were as follows: Neutrophil lymphocyte ratio: Clinical spectrum and outcome: The cohort was classified as asymptomatic (n =4, 18.1%), mild (13, 59.1%), moderate (n = 2, 9.1%) and severe cases (n = 3, 13.6%). WHO ordinal scale of COVID-19 for the cohort included scales of 1(n = 1, 4.5%), 2(n =1, 4.5%), 3(n = 15, 68.3%), 4(n = 2, 9.2%), 5(n = 1, 4.5%), 6(n = 1, 4.5%), 7(n = 1, 4.5%) and 8(n = 1, 4.5%). The most common symptoms reported were depression (n = 14, 63.6%), sleep disturbances (n =13, 59%), cough (n =13, 59%), fever (n =13, 59%), fatigue (n = 9, 40.9%), anxiety (n = 9, 40.9%).

Radiological involvement was reported in most of the cases (n=13, 59%) but there was higher with increasing ordinal scale. (n=8, 47% vs n = 5,100%; p-value: 0.05) MMF was stopped (n =18, 81.8%) or tapered (n =4, 18.1%) in most of the cases and there was no difference between the two groups. Likewise, CNI was stopped (n = 1, 4.5%) or tapered (n = 7, 31.8%) in few cases. The common therapeutics used were remdesivir (n =13, 59%), steroids (n = 9, 40.9%) and anticoagulation (n =8, 36.4%). Acute kidney injury (n = 10, 45.4%) was reported in almost half of the cases.

Comparative analysis: Table 3 shows comparison of 3 groups of early COVID-19(n=22), overall COVID-19(n =1049) and waitlisted patients (n = 1703).

In the analysis, early COVID-19 cases had relatively lesser mortality (n= 1, 4.5% vs n = 87, 8.5%; p-value: 1) compared to COVID-19 in KTR beyond 1 month. The proportion of mild cases (n = 13, 59.1% vs 398, 38.7%; pvalue: 0.07) were higher in early COVID-19 and lower in moderate (n = 2, 9.1% vs n= 279, 27.1%; p-value: 0.08) cases compared to COVID-19 in KTR beyond 1month.There was a trend towards lesser severity and mortality in early COVid-19 but the difference was statistically not significant.

On comparison, the COVID-19 severity between overall KTR and waitlisted showed higher severity in the The reported incidence of 2% early COVID-19 in our study was quite low. The exact source of infection is difficult to elucidate but in only 4 cases, hospital acquired infection occurred. Moreover, all donors were tested thrice negative for COVID-19 before transplant and none of the donors had a history of recovery from COVID-19 prior to the nephrectomy, so a chance of donor-derived transmission was minimized.

Decision to tailor the immunosuppression protocol routinely during COVID-19 is tricky and controversial. There have been many reports of transplant centers reducing the immunosuppression protocol during COVID-19 era. 19, 20 The authors have previously reported no change in immunosuppression in their study of COVID-19 recovered donor or transplant candidate, and found no COVID-19 related or unrelated complications in the follow-up. A recent US data showed reduction in lymphocyte depleting agent in COVID-19 era and a trend of increase in IL-2 blockers. 21 Another study reported a 30% increase in the IL-2 blocker use in the COVID-19 era. 22 In our report, there was no change in the induction or immunosuppression regimen routinely in the centers in the 838 transplants performed. In our report, we have precautionary tailored the immunosuppression even in mild and asymptomatic cases of early COVID-19. However, there are evidences to support that reduction in immunosuppression may not necessarily contribute in decreasing the mortality or severity. 23, 24 

Data has been published mostly from the developed world, but there is huge discrepancy in the management protocol, severity and mortality. Hence a definitive conclusion from previous studies is difficult. There are some reports of bad outcome associated with early COVID-19 in transplants. Kędzierska-Kapuza K et al reported one kidney transplant recipient with higher severity in early COVID-19. 25 Abuzeineh M et al reported poor outcome in a deceased donor kidney transplant with early COVID-19. 26 Akalin et al showed two cases, both of whom succumbed. 27 Banerjee et al showed two early COVID-19 cases with severe disease. 28 Lima et al, showed negative impact of COVID-19 in five heart transplants. 29 Tchana-Sato et al reported two fatalities in perioperative COVID-19 heart transplantation with COVID-19 30 Keller et al detailed a deceased donor lung transplant who acquired early covid-19 required mechanical ventilation. 31 Dale et al described two cases of early liver transplant who contracted severe COVID-19 and recovered. 32 Liver transplants had bad outcome, mostly related to comorbidities and not due to immunosuppression. 33 In a contrasting observation, there are also reports of mild illness.

Kolonko et al described 3 kidney and 1 liver transplants with early COVID-19 having good outcome. 34 Decker et al reported mild COVID-19 in a heart transplant with prolonged infectivity. 35 Massoumi H et al, reported liver transplant recipients with early COVID-19 having a favorable course. 36 

In international surveys of the waitlisted patients, majority of the patients were willing for resuming transplant. 39, 40 The data comparing the burden of COVID-19 in two groups are conflicting. A recently published preliminary UK data, showed KTR suffering from higher mortality compared to waitlisted. 41 A national UK registry showed higher mortality in KTR compared to waitlisted, with increasing age as most important predictor for mortality. 42 ERA-EDTA registry showed 1.28 times higher mortality in KTR compared with matched waitlisted patients.

Contrarily, there are also data suggesting worse outcomes in waitlisted compared to KTR. The European Renal Association COVID-19 Database study reportedly found patients within higher mortality in waitlisted compared to transplant patients. 43 A USA study reported higher mortality in waitlisted patients. 44 A French registry showed higher mortality in waitlisted patients, concluding safety of resuming transplantation in low viral load areas. In our report, the severity of COVID-19 along with the mortality in waitlisted patients is significantly higher from the transplant group. Moreover, there was no differential mortality observed in the early COVID-19 group. 1 Abbreviations: Data expressed as numbers (percentage) or median (Inter-quartile range) as appropriate. Fisher test or Chi square test with Yate's correction used for calculating p-value; WHO ordinal scale ≤ 3: All patients at home or hospitalized on air while ≥ 4 is any form of oxygen requirement, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker. 

Vaccination will play a prime role in combating COVID-19. And immunizing pretransplant patients prior to transplantation will be the new dictum in COVID-19 era. Indian authorities have approved three vaccines ChAdOx1 nCoV-19, BBV152 and sputnik V as of April 2021. As a staged approach for vaccination, individuals with only 45 years above were allowed till April 2021 and people with over 18 years are included for inoculation in May 2021. While vaccination is being effectively implemented in many nations, India is battling its way out to inoculate such a bulk population. Currently, a vast majority of waitlisted patients and transplant candidates are unvaccinated in India. In our study where 831 transplant candidates underwent transplant, none received vaccination prior to surgery. The reports of adequate antibody response to COVID-19 vaccine in dialysis patients are encouraging. 45 Conversely, recently reports of low immunogenicity of COVID-19 vaccine in organ transplants have raised alarm bell for further research in the field of vaccine and transplantation. 46, 47, 48. Strength of the study: The study describes the COVID-19 presentation and outcome in early transplants, and is the largest cohort from developing world reported till date. The large sample sized data of KTR and waitlisted patients further add to the study. The study involved large number of patients and so applicability or universalization of the study is ensured. We found the incidence of early COVID-19 as low and with favorable outcome. The telemedicine used for managing patients discharged after transplant proved to be an effective tool for preventing spread of infection. The observations from the study can pioneer transplant centers to further boost their transplant activity while undertaking all preventive measures. More data are needed to better streamline the treatment protocol in peri transplant period. Inflammatory phenotype was associated with high mortality in large meta-analysis both in general and transplant patients. 49

Limitations: This retrospective analysis had few inherent limitations. Firstly, the results cannot be completely applied for other solid organ transplantation. Although the fact that cohort had high immunological risk of receiving superadded immunosuppression negates this limitation. Secondly, COVID-19 has shown wide diversity in mortality and treatment modalities worldwide, so results should be interpolated accordingly. Thirdly a larger sample size of early COVID-19 cases could have enhanced the comparison done.

We suggest the reason for cessation of transplantation shouldn't be the fear of contracting COVID-19 in early post renal transplant period. The decision to halt should be primarily based on the resources available and the regional COVID-19 surge. The important message conveyed from our study is that with the available safety measures, it is clear that transplant centers should proceed with transplantation, checking the COVID-19 surge in their localities.

Data availability statement: Data will be available from the corresponding author on reasonable request.

World health organization. WHO Coronavirus (COVID-19) Dashboard

Resuming liver transplantation amid the COVID-19 pandemic. The lancet Gastroenterology & hepatology

COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature

Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study From India

Impact of COVID-19 in solid organ transplant recipients

COVID-19 in transplant recipients: The Spanish experience

Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish experience

Outcomes of Coronavirus Infectious Disease -19 (COVID-19) in Solid Organ Transplant Recipients: A Propensity Matched Analysis of a Large Research Network

Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease in A High-Volume Transplant Center

The Full Spectrum of COVID-19 Development and Recovery Among Kidney Transplant Recipients

Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort

Ministry of Health and Family Welfare

KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation

KDIGO clinical practice guideline on the evaluation and care of living kidney donors

NOTTO transplant specific guidelines with reference to COVID-19

Is it Safe to Be Transplanted From Living Donors Who Recovered From COVID-19? Experience of 31 Kidney Transplants in a Multicenter Cohort Study From India

A Multicenter Cohort Study From India of 75 Kidney Transplants in Recipients Recovered After COVID-19

COVID-19 Therapeutic Trial Synopsis Draft

Early impact of COVID-19 on transplant center practices and policies in the United States

Organ procurement and transplantation during the COVID-19 pandemic

Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic

Modification in induction immunosuppression regimens to safely perform kidney transplants amid the COVID-19 pandemic: a single center retrospective study

COVID-19 in solid organ transplant: A multi-center cohort study

Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients

The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy

COVID-19 Early After a Deceased Donor Kidney Transplant Surgery

Covid-19 and kidney transplantation

COVID-19 infection in kidney transplant recipients. Kidney international

COVID-19 in recent heart transplant recipients: Clinicopathologic features and early outcomes

Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients

Early COVID-19 infection after lung transplantation

Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients

Coronavirus Disease 2019 in the Early Postoperative Period of Liver Transplantation: Is the Outcome Really So Positive?

COVID-19 infection in solid organ transplant recipients: A single-center experience with patients immediately after transplantation

Prolonged SARS-CoV-2 shedding and mild course of COVID-19 in a patient after recent heart transplantation

Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability

SARS-CoV-2 infection in two patients following recent lung transplantation

COVID-19 in solid organ transplant recipients: No difference in survival compared to general population

Impact of Covid-19 on kidney transplant and waiting list patients: Lessons from the first wave of the pandemic

Resuming Deceased Donor Kidney Transplantation in the COVID-19 Era: What Do Patients Want?

Outcomes of Renal Transplant Recipients With SARS-CoV-2 Infection in the Eye of the Storm: A Comparative Study With Waitlisted Patients

SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study

COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

COVID-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Association of elevated inflammatory markers and severe COVID-19: A meta-analysis

We acknowledge professor Stephen Tullius, Harvard Medical School for his valuable opinion and edits in the manuscript. We also express our sincere gratitude to all the resident doctors and health care staffs who are tirelessly doing a mammoth job of managing the COVID-19 cases in India, despite facing resource crisis.